According to a press release, the primary focus of Apex Trials is Phase I / Pharmacokinetic studies – Phase IV Studies for both pharmaceutical and nutraceuticals targeting a range of indications, including: Cardiovascular Disease, Hypertension, Dyslipidemia, Diabetes, Irritable bowel syndrome, and Weight management.
"Over the past decade, I have been able to witness and appreciate the evolution of our clinical trials unit,” said Katie Keene, Clinic Supervisor. “This latest change is our biggest and best yet as it will allow us to expand our focus beyond food and natural health product trials to include pharmaceutical trials, further growing our site’s portfolio of offerings.”
Apex Trials operates a 17,000 sq ft clinical trial suite under the leadership of Principal Investigator Dr. Anthony Bier, and is headquartered in Southwestern Ontario, Canada.
“We are excited to launch our clinical trial site under the brand of Apex Trials,” added Joshua Baisley, SVP Clinical Operations. “We deliberately separated the operations of our site from our CRO activities many years ago to differentiate ourselves from our competitors and demonstrate our commitment to compliance thereby protecting our Sponsor’s investment. With a team of over 20 staff, 20 years of clinical trial experience, and a client-centric approach.”